SIRT6 and obesity disorder: Research indicates that theaflavins TF1, TF2a, and TF3 enhance glucose and lipid metabolism in mice on a HFD by activating the SIRT6/AMPK/SREBP-1/FASN pathway, thus effectively mitigating obesity symptoms (90).